DE69019164T2 - Verbessertes meningokokkale polysaccharidkonjugatvakzin. - Google Patents

Verbessertes meningokokkale polysaccharidkonjugatvakzin.

Info

Publication number
DE69019164T2
DE69019164T2 DE69019164T DE69019164T DE69019164T2 DE 69019164 T2 DE69019164 T2 DE 69019164T2 DE 69019164 T DE69019164 T DE 69019164T DE 69019164 T DE69019164 T DE 69019164T DE 69019164 T2 DE69019164 T2 DE 69019164T2
Authority
DE
Germany
Prior art keywords
polysaccharide
group
butanoyl
pentanoyl
gbmp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69019164T
Other languages
German (de)
English (en)
Other versions
DE69019164D1 (de
Inventor
Harold J. Gloucester On K1J 6G6 Jennings
Francis Ottawa On K1M 1T5 Michon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council of Canada
Original Assignee
National Research Council of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council of Canada filed Critical National Research Council of Canada
Application granted granted Critical
Publication of DE69019164D1 publication Critical patent/DE69019164D1/de
Publication of DE69019164T2 publication Critical patent/DE69019164T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DE69019164T 1989-12-14 1990-12-13 Verbessertes meningokokkale polysaccharidkonjugatvakzin. Expired - Fee Related DE69019164T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44819589A 1989-12-14 1989-12-14
PCT/CA1990/000437 WO1991008772A1 (en) 1989-12-14 1990-12-13 Improved meningococcal polysaccharide conjugate vaccine

Publications (2)

Publication Number Publication Date
DE69019164D1 DE69019164D1 (de) 1995-06-08
DE69019164T2 true DE69019164T2 (de) 1995-09-07

Family

ID=23779371

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69019164T Expired - Fee Related DE69019164T2 (de) 1989-12-14 1990-12-13 Verbessertes meningokokkale polysaccharidkonjugatvakzin.

Country Status (30)

Country Link
US (3) US5576002A (cg-RX-API-DMAC7.html)
EP (1) EP0504202B1 (cg-RX-API-DMAC7.html)
JP (1) JP2637845B2 (cg-RX-API-DMAC7.html)
KR (1) KR0158436B1 (cg-RX-API-DMAC7.html)
CN (4) CN1049223C (cg-RX-API-DMAC7.html)
AR (1) AR243934A1 (cg-RX-API-DMAC7.html)
AT (1) ATE121947T1 (cg-RX-API-DMAC7.html)
AU (1) AU641715B2 (cg-RX-API-DMAC7.html)
BR (1) BR9007917A (cg-RX-API-DMAC7.html)
CA (1) CA2071811C (cg-RX-API-DMAC7.html)
CZ (1) CZ283530B6 (cg-RX-API-DMAC7.html)
DE (1) DE69019164T2 (cg-RX-API-DMAC7.html)
DK (1) DK0504202T3 (cg-RX-API-DMAC7.html)
ES (1) ES2071288T3 (cg-RX-API-DMAC7.html)
FI (2) FI104539B (cg-RX-API-DMAC7.html)
HR (1) HRP920872A2 (cg-RX-API-DMAC7.html)
HU (2) HU218146B (cg-RX-API-DMAC7.html)
IE (1) IE68414B1 (cg-RX-API-DMAC7.html)
IL (1) IL96676A (cg-RX-API-DMAC7.html)
IN (1) IN171747B (cg-RX-API-DMAC7.html)
NO (2) NO305275B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ236471A (cg-RX-API-DMAC7.html)
PH (1) PH30305A (cg-RX-API-DMAC7.html)
PL (2) PL166659B1 (cg-RX-API-DMAC7.html)
RO (1) RO111416B1 (cg-RX-API-DMAC7.html)
RU (1) RU2105568C1 (cg-RX-API-DMAC7.html)
SI (1) SI20008B (cg-RX-API-DMAC7.html)
WO (1) WO1991008772A1 (cg-RX-API-DMAC7.html)
YU (1) YU24391A (cg-RX-API-DMAC7.html)
ZA (1) ZA9010065B (cg-RX-API-DMAC7.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648241A (en) * 1989-09-15 1997-07-15 The General Hospital Corporation Conjugate vaccine against group B streptococcus
KR0158436B1 (ko) * 1989-12-14 1998-12-01 피에르 오. 페론 개선된 수막염균성 폴리사카라이드 결합체 백신
CA2145397C (en) * 1992-09-24 2007-10-30 Harold J. Jennings Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5679654A (en) * 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5700787A (en) * 1994-09-02 1997-12-23 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5747287A (en) * 1995-04-28 1998-05-05 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
JP4233113B2 (ja) * 1995-06-07 2009-03-04 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム 多糖類抗原−キャリア蛋白接合体および遊離キャリア蛋白を有してなるワクチン
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
ZA97248B (en) * 1996-01-18 1997-07-18 Rohm & Haas Method for identifying and quantifying polymers utilizing immunoassay techniques
DE69708318T3 (de) † 1996-08-27 2006-11-16 Novartis Vaccines and Diagnostics, Inc., Emeryville Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
US6048527A (en) * 1996-08-27 2000-04-11 Chiron Corporation Antibodies that define unique Meningococcal B epitopes and vaccine compositions
US6426074B1 (en) * 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
JP2002506448A (ja) 1997-06-24 2002-02-26 カイロン コーポレイション 抗髄膜炎菌ワクチン組成物を使用して成体を免疫する方法
PT1007546E (pt) * 1997-08-27 2009-04-24 Childrens Hosp & Res Ct Oak Compostos miméticos moleculares de epítopos de meningococos do serogrupo b
WO1999032653A1 (en) 1997-12-23 1999-07-01 North American Vaccine, Inc. Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugates vaccines
WO2000010599A2 (en) * 1998-08-19 2000-03-02 North American Vaccine, Inc. IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
RU2249463C2 (ru) * 1998-08-19 2005-04-10 Бакстер Хелфкэа С.А. Иммуногенный конъюгат бета-пропионамид-связанного полисахарида с белком, использующийся в качестве вакцины
US6436653B1 (en) 1998-12-15 2002-08-20 Exiqon A/S Method for introduction of reporter groups into bacterial lipopolysaccharide-derived carbohydrates and the subsequent coupling of such derivatives onto solid surfaces
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
US6518037B2 (en) * 1999-11-12 2003-02-11 University Of Iowa Research Foundation Two-component system that controls bacterial membrane synthesis
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
GB0011108D0 (en) * 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
JP2004529643A (ja) 2001-04-17 2004-09-30 カイロン コーポレイション 機能活性抗体を誘発する髄膜炎菌性ｂエピトープの分子模倣物
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
WO2003080678A1 (en) * 2002-03-26 2003-10-02 Chiron Srl Modified saccharides having improved stability in water
NZ536859A (en) * 2002-05-14 2007-11-30 Chiron Srl Mucosal combination vaccines for bacterial meningitis
RU2494758C2 (ru) * 2002-08-02 2013-10-10 ГлаксоСмитКлайн Байолоджикалз с.а. Нейссериальные вакцинные композиции, содержащие комбинацию антигенов
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
WO2004089407A2 (en) 2003-03-31 2004-10-21 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
KR101113726B1 (ko) 2003-08-12 2012-02-27 리폭센 테크놀로지즈 리미티드 단백질 유도 및 컨쥬게이션용 시알산 유도체
MXPA06015107A (es) * 2004-06-23 2007-03-26 Childrens Hosp & Res Ct Oak Derivados de polisacaridos y sus usos en la induccion de una respuesta inmune.
US8148335B2 (en) 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
DK2283857T3 (da) 2005-06-27 2019-10-28 Glaxosmithkline Biologicals Sa Vaccinesammensætning omfattende konjugerede native N. Meningitidis kapselpolysaccharider
US8206726B2 (en) 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
GB0611914D0 (en) 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
EP1872791A1 (en) * 2006-06-30 2008-01-02 Institut Pasteur Use of bacterial polysaccharides for biofilm inhibition
ES2621359T3 (es) * 2007-06-20 2017-07-03 Pfizer Ireland Pharmaceuticals Polisacáridos modificados para vacunas conjugadas
JP2011506334A (ja) 2007-12-07 2011-03-03 ノバルティス アーゲー 免疫応答を誘導するための組成物
WO2010083477A2 (en) 2009-01-16 2010-07-22 University Of Maryland, Baltimore Broad spectrum vaccine against non-typhoidal salmonella
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
EP2752403A1 (de) * 2013-01-08 2014-07-09 Sika Technology AG Amin für emissionsarme Epoxidharz-Produkte
CN113637040A (zh) 2015-08-19 2021-11-12 哈佛学院院长及董事 脂化psa组合物和方法
CA3030974A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
IL267733B2 (en) * 2017-01-31 2023-10-01 Pfizer Neisseria meningitidis compositions and methods thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) * 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4644059A (en) * 1982-07-06 1987-02-17 Connaught Laboratories, Inc. Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
KR0158436B1 (ko) * 1989-12-14 1998-12-01 피에르 오. 페론 개선된 수막염균성 폴리사카라이드 결합체 백신

Also Published As

Publication number Publication date
AU6898791A (en) 1991-07-18
RU2105568C1 (ru) 1998-02-27
IE68414B1 (en) 1996-06-12
FI922737A0 (fi) 1992-06-12
CN1055541A (zh) 1991-10-23
IL96676A (en) 1996-09-12
NO305275B1 (no) 1999-05-03
AU641715B2 (en) 1993-09-30
IE904513A1 (en) 1991-06-19
CA2071811C (en) 2003-11-04
CN1100428A (zh) 1995-03-22
CN1096516A (zh) 1994-12-21
IL96676A0 (en) 1991-09-16
ATE121947T1 (de) 1995-05-15
NO922316L (no) 1992-08-14
CZ628490A3 (en) 1997-12-17
CZ283530B6 (cs) 1998-04-15
AR243934A1 (es) 1993-09-30
HRP920872A2 (en) 1997-06-30
EP0504202A1 (en) 1992-09-23
SI20008A (sl) 2000-02-29
FI19991917L (fi) 1999-09-09
IN171747B (cg-RX-API-DMAC7.html) 1992-12-26
RO111416B1 (ro) 1996-10-31
US5683699A (en) 1997-11-04
WO1991008772A1 (en) 1991-06-27
CN1036522C (zh) 1997-11-26
ES2071288T3 (es) 1995-06-16
HU9201966D0 (en) 1992-10-28
NZ236471A (en) 1992-10-28
PL166659B1 (pl) 1995-06-30
BR9007917A (pt) 1992-10-20
PL166035B1 (pl) 1995-03-31
NO973311D0 (no) 1997-07-17
SI20008B (en) 2001-02-28
HU218146B (hu) 2000-06-28
CN1036504C (zh) 1997-11-26
HUT64480A (en) 1994-01-28
FI104539B (fi) 2000-02-29
CN1100656A (zh) 1995-03-29
KR0158436B1 (ko) 1998-12-01
PL288271A1 (en) 1991-12-16
CN1049223C (zh) 2000-02-09
CA2071811A1 (en) 1991-06-15
US5902586A (en) 1999-05-11
FI19991917A7 (fi) 1999-09-09
EP0504202B1 (en) 1995-05-03
CN1072506C (zh) 2001-10-10
NO922316D0 (no) 1992-06-12
DE69019164D1 (de) 1995-06-08
PH30305A (en) 1997-02-20
JPH05505392A (ja) 1993-08-12
YU24391A (sh) 1995-12-04
NO973311L (no) 1992-08-14
NO307835B1 (no) 2000-06-05
DK0504202T3 (da) 1995-10-02
JP2637845B2 (ja) 1997-08-06
US5576002A (en) 1996-11-19
ZA9010065B (en) 1992-02-26

Similar Documents

Publication Publication Date Title
DE69019164T2 (de) Verbessertes meningokokkale polysaccharidkonjugatvakzin.
DE69627652T2 (de) Verbesserte meningokokken polysaccharid-konjugat vakzine
DE3787995T2 (de) Immunogen Konjugate.
DE69708318T2 (de) Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
DE69118389T2 (de) Verbesserte vakzinzusammensetzung
DE69518978T2 (de) Gruppe a streptokokkenpolysaccharide immunogen-zusammensetzungen und verfahren
DE69231673T2 (de) Escherichia coli impfstoffe auf der basis von o-polysaccharid-protein konjugaten
DE69627149T2 (de) Antigene polysaccharidfragmente mit einer terminalen 2,5-anhydro-d-mannosegruppevon gruppe b-streptococcus, typ ii und typ iii, und daraus hergestellte konjugatimpfstoffe
DE69331495T2 (de) Impfstoffe gegen neisseria meningitidis gruppe c
DE69518919T2 (de) Autoantikörper enthaltende zusammensetzung für tumorbehandlung und -vorbeugung
DE60026691T2 (de) Staphylococcus-antigene und impstoffe
EP0220387B1 (de) Konjugatimpfstoffe gegen Infektionen durch gramnegative Bakterien, Verfahren zu deren Herstellung sowie Verwendung derselben
DE69925187T2 (de) Antigenkonjugate von konservierten Lipooligosacchariden aus gram-negativen Bakterien
DE69231663T2 (de) Polysaccharid-protein-konjugate
DE69330464T2 (de) Gruppe b streptococcus typ ii und typ v polysaccharid-protein konjugate als impfstoffe
DE69032855T2 (de) Antiidiotypischer antikörper, der eine immunantwort gegen ein glykosphingolipid induziert und seine verwendung
DE69428969T2 (de) Impfstoff geeignet eine Immunantwort gegen N-Glycolysierte-Gangliosiden hervorzurufen und ihre Anwendung als Antikrebsmittel
AT397803B (de) Humaner monoklonaler antikörper und hybridom zur herstellung desselben
DE68915046T2 (de) Haemophilus influenzae Typ B Polysaccharid-Aussermembranprotein-Konjugat als Impfstoff.
DE68921908T2 (de) Zell-assoziierte Glucosyltransferase, Antikörper dagegen und eine diese enthaltende Zusammensetzung zur Prophylaxe von Karies.
DE69130536T2 (de) Adhäsionsrezeptoren für pathogene oder opportunistische mikroorganismen
DE69525638T2 (de) Synthese eines typhusimpfstoffes unter verwendung eines polysaccharids aus einer pflanze oder einer frucht
DE19821859A1 (de) Darstellung immunogener (Kapsel-)Polysaccharid-Konjugate durch orientierte Kupplung synthetischer T-Zell-Epitope zur Erzeugung von Vakzinen gegen N.meningitidis
DE68924963T2 (de) Zusammensetzungen und Methoden zur Behandlung und Vorbeugung von Gram-Negativen-Infektionen.
DE102006053385B4 (de) Enterococcus faecalis-Antigen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee